Highest development stage: Preclinical

Development dropped

Mechanism of Action/Target pathogen: Mycobacterium avium dihydrofolate reductase inhibitors; most active compound in series against Mycobacterium avium

Reason dropped: These were presented in early stages of the work. They suggest other compounds in the series in development which better solubility and selectivity. It is likely, these were superseded.

Additional information: Barrow EW, Suling WJ, Seitz, LE, etc. Screening of new selective inhibitors for Mycobacterium avium DHFR. Poster F-734 44th-ICAAC 2004;206.